Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Plasma IL-2 and Symptoms Response after Acute Gluten Exposure in Subjects With Celiac Disease or Nonceliac Gluten Sensitivity
Cartee, Amanda K. , Choung, Rok Seon , Wang, Suyue , Dyke, Carol T. Van, Hinson, Chadrick A., Marietta, Eric, Katzka, David A. , Nehra, Vandana, Grover, Madhusudan , King, Katherine S. , Van Dyke, Carol T, Dzuris, John L. , Anderson, Robert P. , Murray, Joseph A. , Choung, Rok Seon

Mayo Clinic

American Journal of Gastroenterology | November 19, 2021 | Volume: 117 | Issue: 2 | Pages: 319-326

10.14309/ajg.0000000000001565 | PMID 34797778 Get It

INTRODUCTION: Treated patients with celiac disease (CeD) and nonceliac gluten sensitivity (NCGS) report acute, transient, incompletely understood symptoms after suspected gluten exposure. To determine whether (i) blinded gluten exposure induces symptoms, (ii) subjects accurately identify gluten exposure, and (iii) serum interleukin-2 (IL-2) levels distinguish CeD from NCGS subjects after gluten exposure. METHODS: Sixty subjects (n = 20 treated, healed CeD; n = 20 treated NCGS; n = 20 controls) were block randomized to a single, double-blind sham (rice flour) or 3-g gluten challenge with 72-hours follow-up. Twelve serial questionnaires (100 mm visual analog scale; pain, bloating, nausea, and fatigue) and 10 serial plasma samples were collected. Mucosal permeability was assessed using both urinary lactulose- 13 C mannitol ratios and endoscopic mucosal impedance. RESULTS: Thirty-five of 40 (83%) subjects with CeD and NCGS reported symptoms with gluten (8 CeD, 9 NCGS) and sham (9 CeD, 9 NCGS) compared with 9 of 20 (45%) controls after gluten (n = 6) and sham (n = 3). There was no significant difference in symptoms among groups. Only 2 of 10 subjects with CeD and 4 of 10 NCGS identified gluten, whereas 8 of 10 subjects with CeD and 5 of 10 NCGS identified sham. A significant plasma IL-2 increase occurred only in subjects with CeD after gluten, peaking at 3 hours and normalizing within 24 hours postchallenge despite no significant intestinal permeability change from baseline. DISCUSSION: Symptoms do not reliably indicate gluten exposure in either subjects with CeD or NCGS. IL-2 production indicates a rapid-onset gluten-induced T-cell activation in CeD despite long-standing treatment. The effector site is unknown, given no increased intestinal permeability after gluten.
Dramatic Reduction of Distant Pancreatic Metastases Using Local Light Activation of Verteporfin with Nab-Paclitaxel
Pigula, Michael , Mai, Zhiming , Anbil, Sriram , Choi, Myung‐Gyu , Maytin, Edward V. , Hasan, Tayyaba , Hasan, Tayyaba , Wang, Kenneth , Pogue, Brian W.

Mayo Clinic

Cancers | November 18, 2021 | Volume: 13 | Issue: 22 | Pages: 5781

10.3390/cancers13225781 | PMID 34830934 Get It

Despite substantial drug development efforts, pancreatic adenocarcinoma (PDAC) remains a difficult disease to treat, and surgical resection is the only potentially curative option. Unfortunately, 80% of patients are ineligible for surgery due to the presence of invasive disease and/or distant metastases at the time of diagnosis. Treatment strategies geared towards reclassifying these patients as surgical candidates by reducing metastatic burden represents the most promising approach to improve long-term survival. We describe a photodynamic therapy (PDT) based approach that, in combination with the first-line chemotherapeutic nab-paclitaxel, effectively addresses distant metastases in three separate orthotopic PDAC models in immunodeficient mice. In addition to effectively controlling local tumor growth, PDT plus nab-paclitaxel primes the tumor to elicit systemic effects and reduce or abrogate metastases. This combination dramatically inhibits (up to 100%) the eventual development of metastases in models of early stage PDAC, and completely eliminates metastasis in 55% of animals with already established distant disease in late-stage models. Our findings suggest that this light activation process initiates local biological and/or physiological changes within the tumor microenvironment that can be leveraged to treat both localized and distant disease, and potentially reclassify patients with previously inoperable disease as surgical candidates.
SURG-04. THE CLINICAL COURSE AND ROLE OF SURGERY IN PEDIATRIC MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A DATABASE STUDY
Lu, Victor M. , Daniels, David, Spinner, Robert J. , Niazi, Toba N., Wang, Shelly , Daniels, David, Levi, Allan D.

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi195-vi195

10.1093/neuonc/noab196.774 Get It

Abstract BACKGROUND Malignant peripheral nerve sheath tumors (MPNST) are rare tumors found throughout the body, with their clinical course in children still to be completely understood. Correspondingly, this study aimed to determine survival outcomes and specific clinical predictors of survival in this demographic from a large national database. METHODS All MPNST patients aged ≤18 year in the U.S. National Cancer Database (NCDB) between 2005-2016 were retrospectively reviewed. Data were summarized and overall survival (OS) was modeled using Kaplan-Meier and Cox regression analyses. RESULTS A total of 251 pediatric MPNST cases were identified. Overall, mean age at diagnosis was 13.1 years (range, 1-18) with there being 132 (53%) females and 119 (47%) males. There were 84 (33%) MPNSTs located in extremities, 127 (51%) less than 1cm in size, and 22 (9%) have metastasis at diagnosis. In terms of treatment, surgery was pursued in 187 (74%) patients, chemotherapy in 116 (46%) patients, and radiation therapy in 129 (61%) patients. Five-year overall survival was estimated to be 52% (95% CI, 45-59%), and with median survival of 64 months (range, 36-136). Multivariate regression revealed older age (HR 1.10, P< 0.01), with metastases at time of diagnosis (HR 2.14, P=0.01), and biopsy only (HR 2.98, P< 0.01) all significantly and independently predicted shorter overall survival. Chemotherapy and radiation therapy were not statistically significant. CONCLUSIONS Pediatric MPNSTs are rare malignant entities, and only approximately half of patients will survive to five years. There remains a clear survival benefit in pursuing maximal safe resection in these patients. As such, judicious workup with meticulous surgical resection by an expert team should then be considered the standard of care for these tumors in children.
NIMG-72. QUANTIFYING INTRA-TUMOR MULTI-GENE HETEROGENEITY OF GBM FROM MRI USING A DATA-INCLUSIVE MACHINE LEARNING ALGORITHM
Hu, Leland , Singleton, Kyle , Sereduk, Christopher, Swanson, Kristin R. , Li, Jing , Swanson, Kristin R , Wang, Lujia , Hawkins‐Daarud, Andrea , Sereduk, Chris , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi145-vi146

10.1093/neuonc/noab196.569 Get It

Abstract Intra-tumor genetic heterogeneity is an important cause of treatment failure of GBM. Using MRI and image-localized biopsies, it is possible to train machine learning (ML) models to predict regional genetic status. However, biopsy samples are limited, making it difficult to train a robust ML model. We proposed a data-inclusive model called Weakly Supervised Ordinal Support Vector Machines (WSO-SVM) which leverages the vast amount of MRI data outside the sparsely sampled biopsy regions to augment the biopsy samples to improve ML accuracy. Our study included a unique dataset of 104 image-localized biopsies with spatially matched multiparametric MRI from 30 untreated Glioblastoma (GBM) patients. Each biopsy sample went through genetic sequencing analysis and our study focused on two GBM hallmark genes, EGFR and PDGFRA. For each gene, a biopsy sample was labeled as “altered” if the copy number of this gene was amplified or a mutation was found, and “non-altered” otherwise. From the localized region of six MRI contrasts from T1gd, T2w, diffusion and perfusion imaging, over 300 texture features were extracted. To account for biopsy sample location uncertainty, six neighboring regions of the biopsy sample including four neighbors two pixels away from the biopsy location and two neighbors on adjacent slices were also included in model training. WSO-SVM achieved 0.83 accuracy, 0.77 sensitivity, and 0.86 specificity for classifying EGFR; 0.77 accuracy, 0.74 sensitivity, and 0.79 specificity for classifying PDGFRA, based on 10-fold cross validation. Furthermore, using the trained models, we generated regional EGFR and PDGFRA alteration maps for each patient within the enhancing and non-enhancing tumoral areas. On average we found a greater proportion of enhancing tumor with co-alteration than non-enhancing tumor, while this trend was reversed when considering only one altered gene. The ratio of EGFR vs PDGFRA alterations was higher in non-enhancing tumor than enhancing tumor.
EXTH-66. ENHANCEMENT OF ANTI-PD-1 THERAPY WITH EXTENDED HALF-LIFE IL-2 IS INDEPENDENT OF MHC CLASS I RESTRICTED ANTIGEN RECOGNITION FOR TREATMENT OF EXPERIMENTAL GLIOMA
Tritz, Zachariah P. , Malo, Courtney S. , Khadka, Roman H., Yokanovich, Lila T. , Hansen, Michael J. , Wang, Chensu , Wittrup, Dane, Johnson, Aaron J. , Ayasoufi, Katayoun , Himes, Benjamin , Fain, Cori E. , Goddery, Emma N. , Jin, Fang , Parney, Ian F. , Moynihan, Kelly D , Irvine, Darrell J , Johnson, Aaron J.

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi178-vi178

10.1093/neuonc/noab196.705 Get It

Abstract Glioblastoma (GBM) is the most common malignant brain tumor in adults, responsible for approximately 225,000 deaths per year. Despite pre-clinical successes, therapeutic interventions have failed to extend patient survival by more than a few months. Anti-PD-1 checkpoint inhibition monotherapy has had efficacy against some tumor types but not GBM. The aim of this study was to determine whether supplementing anti-PD-1 checkpoint blockade with an engineered extended half-life IL-2 could improve outcomes in a preclinical model of disease. Our enhanced checkpoint blockade (ECB) strategy reliably cures approximately50% of C57BL/6 mice bearing orthotopic GL261 gliomas and extended median survival even in the mice that eventually succumbed. This therapy generates robust immunologic responses, features of which include secondary lymphoid organ enlargement and increased activation status of both CD4 and CD8 T cells. Further, many of the characteristics of brain-tumor mediated peripheral immunosuppression, including MHC class II downregulation on APCs, are prevented by ECB combination therapy. This immunity is durable, with long-term ECB survivors able to resist GL261 rechallenge. Notably, ECB’s efficacy is independent of host MHC class I restricted antigen presentation, being equally efficacious in MHC class I and CD8 T cell deficient mice. Conversely, ECB combination therapy is reliant on CD4 T cells and their depletion abrogates the therapy’s survival benefit. Our data shows ECB combination immunotherapy to be efficacious against the GL261 glioma model through an MHC class I independent mechanism, enhancing its off-the-shelf translational appeal relative to strategies requiring extensive knowledge of tumor-specific antigens.
EPCO-02. GERMLINE SINGLE NUCLEOTIDE POLYMORPHISM rs55705857 AT 8q24 INTERACTS WITH SOMATIC IDH1 MUTATION TO ENHANCE HUMAN GLIOMA FORMATION
Yanchus, Connor , Kollmeyer, Thomas , Ali, Asma, Decker, Paul, Kosel, Matthew , Caron, Alissa, Burns, Terence, Wrensch, Margaret , Eckel‐Passow, Jeanette E. , Jenkins, Robert B. , Drucker, Kristen , Panda, Arijit , Giannini, Caterina , Abyzov, Alexej , Wang, Liguo , Wiencke, John K. , Lachance, Daniel Honore , Schramek, Daniel

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi1-vi1

10.1093/neuonc/noab196.001 Get It

Abstract BACKGROUND Determination of the causation of germline single nucleotide polymorphisms (SNPs) located in non-coding regions of the genome is challenging. The genomic region of 8q24 has been identified as important in many kinds of cancer, linked to a topologically associated domain (TAD) encompassing MYC; this TAD contains a GWAS SNP (rs55705857) associated with IDH-mutant glioma. METHODS Germline genotyping data from 622 IDH-mutant glioma and 668 controls were used to fine map the rs55705857 locus by detailed haplotype analysis. Chromatin immunoprecipitation sequencing (ChIP-seq) of histone markers H3K4me1, H3K4me3, H3K27ac and H3K36me3 was performed on normal brain samples (n=8) and human glioma samples (n=11 IDH-wt and 52 IDH-mut). RNAseq from 9 normal and 83 brain tumors (n=26 IDH-wt and 55 IDH-mut) were used to assess differential gene expression. RESULTS Fine-mapping identified rs55705857 SNP as the most likely causative allele (OR=8.69; p<0.001) within 8q24 for the development of IDH-mutant glioma. At rs55705857, both H3K27ac and H3K4me1 in IDH-mutant vs IDH-wt tumors were increased 3.05- and 1.58-fold, respectively (DiffBind; p=5.81×10-7 and p=2.31×10-3). ChromHMM analysis of the marks indicated that promoter and enhancer functions were significantly increased, and the activity broadened at rs55705857 in IDH-mut gliomas compared to IDH-wt tumors and normal brain samples. This enhancement correlated with significant increased MYC expression in IDH-mut gliomas (p=3.1×10-13), as well as alterations of Myc signaling targets. Publicly available ATACseq, ChIPseq and long-range DNA interaction data demonstrated that the rs55705857 locus is open and interacts with the MYC promoter. CONCLUSIONS Fine-mapping of the 8q24 locus provided strong evidence that rs55705857 is the causative 8q24 locus associated with IDH-mut glioma. Functional experiments suggest that IDH mutation facilitates rs55705857 interaction with MYC to alter downstream MYC targets.
Sex-Based Differences in Outcomes With Percutaneous Transcatheter Repair of Mitral Regurgitation With the MitraClip System: Transcatheter Valve Therapy Registry From 2011 to 2017
Villablanca, Pedro , Vemulapalli, Sreekanth , Stebbins, Amanda , Dai, Dadi, So, Chak-Yu , Eng, Marvin H. , Wang, Dee Dee , Frisoli, Tiberio , Lee, James , Kang, Guson , Ibrahim, Homam , Staniloae, Cezar , Gaba, Prakriti , Lemor, Alejandro , Finn, Matthew , Leon, Martin B. , Villablanca, Pedro A , Lee, James C , Staniloae, Cezar , Lemor, Alejandro , Ramakrishna, Harish , Shah, Binita , Wang, Dee Dee , Szerlip, Molly , Williams, Mathew , O’Neill, William W. , Shah, Binita

Mayo Clinic

Circulation: Cardiovascular Interventions | November 16, 2021 | Volume: 14 | Issue: 11 | Pages: No page available

10.1161/circinterventions.120.009374 | PMID 34784236 Get It

Background: Women have a higher rate of adverse events after mitral valve surgery. We sought to evaluate whether outcomes after transcatheter edge-to-edge repair intervention by sex have similar trends to mitral valve surgery. Methods: The primary outcome was 1-year major adverse events defined as a composite of all-cause mortality, stroke, and any bleeding in the overall study cohort. Patients who underwent transcatheter edge-to-edge repair for mitral regurgitation with the MitraClip system in the Society of Thoracic Surgery/American College of Cardiology Transcatheter Valve Therapy registry were evaluated. Linked administrative claims from the Centers for Medicare and Medicaid Services were used to evaluate 1-year clinical outcomes. Associations between sex and outcomes were evaluated using a multivariable logistic regression model for in-hospital outcomes and Cox model for 1-year outcomes. Results: From November 2013 to March 2017, 5295 patients, 47.6% (n=2523) of whom were female, underwent transcatheter edge-to-edge repair. Females were less likely to have >1 clip implanted ( P <0.001) and had a lower adjusted odds ratio of device success (adjusted odds ratio, 0.78 [95% CI, 0.67–0.90]), driven by lower odds of residual mitral gradient <5 mm Hg (adjusted odds ratio, 0.54 [CI, 0.46–0.63]) when compared with males. At 1-year follow-up, the primary outcome did not differ by sex. Female sex was associated with lower adjusted 1-year risk of all-cause mortality (adjusted hazard ratio, 0.80 [CI, 0.68–0.94]), but the adjusted 1-year risk of stroke and any bleeding did not differ by sex. Conclusions: No difference in composite outcome of all-cause mortality, stroke, and any bleeding was observed between females and males. Adjusted 1-year all-cause mortality was lower in females compared with males.
International expert consensus on precision anatomy for minimally invasive pancreatoduodenectomy: PAM‐HBP surgery project
Nagakawa, Yuichi , Nakata, Kohei , Nishino, Hitoe , Ohtsuka, Takao , Ban, Daisuke , Asbun, Horacio J. , Boggi, Ugo , He, Jin , Kendrick, Michael L. , Palanivelu, Chinnusamy , Liu, Rong , Wang, Shin‐E , Tang, Chung‐Ngai, Takaori, Kyoichi , Hilal, Mohammad Abu , Jang, Jin‐Young , Kang, Chang Moo , Kooby, David A. , Nakamura, Yoshiharu , Shrikhande, Shailesh V. , Wolfgang, Christopher L. , Yiengpruksawan, Anusak, Watanabe, Yusuke , Kozono, Shingo , Ciria, Rubén , Garbarino, Giovanni Maria , Higuchi, Ryota , Ishikawa, Yoshiya , Maekawa, Aya , Murase, Yoshiki, Kunzler, F. , Wang, Zizheng , Sakuma, Leon, Takishita, Chie, Osakabe, Hiroaki , Endo, Itaru , Tanaka, Masao , Yamaue, Hiroki , Tanabe, Minoru , Wakabayashi, Go , Tsuchida, Akihiko , Goh, Brian K P , Honda, Goro , Jang, Jin-Young , Kang, Chang Moo , Yoon, Yoo-Seok , Ciria, Ruben , Kunzler, Filipe , Endo, Itaru , Nakamura, Masafumi , Nakata, Kohei , Tang, Chung Ngai, Honda, Goro , Berardi, Giammauro , Ikenaga, Naoki , Zimmitti, Giuseppe

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | November 16, 2021 | Volume: 29 | Issue: 1 | Pages: 124-135

10.1002/jhbp.1081 | PMID 34783176 Get It

AbstractBackgroundThe anatomical structure around the pancreatic head is very complex and it is important to understand its precise anatomy and corresponding anatomical approach to safely perform minimally invasive pancreatoduodenectomy (MIPD). This consensus statement aimed to develop recommendations for elucidating the anatomy and surgical approaches to MIPD.MethodsStudies identified via a comprehensive literature search were classified using the Scottish Intercollegiate Guidelines Network method. Delphi voting was conducted after experts had drafted recommendations, with a goal of obtaining >75% consensus. Experts discussed the revised recommendations with the validation committee and an international audience of 384 attendees. Finalized recommendations were made after a second round of online Delphi voting.ResultsThree clinical questions were addressed, providing six recommendations. All recommendations reached at least a consensus of 75%. Preoperatively evaluating the presence of anatomical variations and superior mesenteric artery (SMA) and superior mesenteric vein (SMV) branching patterns was recommended. Moreover, it was recommended to fully understand the anatomical approach to SMA and intraoperatively confirm the SMA course based on each anatomical landmark before initiating dissection.ConclusionsMIPD experts suggest that surgical trainees perform resection based on precise anatomical landmarks for safe and reliable MIPD.
PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Ga‐PSMA‐11 PET Using Cyclotron‐Produced 68Ga
Thompson, Scott M. , Suman, Garima , Chen, Zongming E., Jondal, Danielle E. , Patra, Anurima , Ehman, Eric C. , Andrews, James C. , Fleming, Chad J. , Welch, Brian T. , Kurup, A. Nicholas , Roberts, Lewis R. , Watt, Kymberly D. , Truty, Mark J. , Smoot, Rory L. , Yin, Jun , Jacobson, Mark, Kemp, Bradley J. , Venkatesh, Sudhakar K. , Johnson, Geoffrey B. , Woodrum, David A. , Goenka, Ajit H. , Chen, Zong-ming E., Kurup, Anil N, Watt, K D , Cleary, Sean P. , Wang, Chen , Fogarty, Zachary C , Venkatesh, Sudhakar K , Roberts, Lewis R , Smoot, Rory L , Johnson, Geoffrey B , Kurup, Anil N , Thompson, Scott , Torbenson, Michael , Heimbach, Julie K. , Tran, Nguyen H. , Mahipal, Amit , Zemla, Tyler , Wang, Chen , Fogarty, Zachary C.

Mayo Clinic

Hepatology Communications | November 16, 2021 | Volume: 6 | Issue: 5 | Pages: 1172-1185

10.1002/hep4.1861 | PMID 34783177 Get It

Prostate‐specific membrane antigen (PSMA) is a validated target for molecular diagnostics and targeted radionuclide therapy. Our purpose was to evaluate PSMA expression in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and hepatic adenoma (HCA); investigate the genetic pathways in HCC associated with PSMA expression; and evaluate HCC detection rate with 68Ga‐PSMA‐11 positron emission tomography (PET). In phase 1, PSMA immunohistochemistry (IHC) on HCC (n = 148), CCA (n = 111), and HCA (n = 78) was scored. In a subset (n = 30), messenger RNA (mRNA) data from the Cancer Genome Atlas HCC RNA sequencing were correlated with PSMA expression. In phase 2, 68Ga‐PSMA‐11 PET was prospectively performed in patients with treatment‐naïve HCC on a digital PET scanner using cyclotron‐produced 68Ga. Uptake was graded qualitatively and semi‐quantitatively using standard metrics. On IHC, PSMA expression was significantly higher in HCC compared with CCA and HCA (P < 0.0001); 91% of HCCs (n = 134) expressed PSMA, which principally localized to tumor‐associated neovasculature. Higher tumor grade was associated with PSMA expression (P = 0.012) but there was no association with tumor size (P = 0.14), fibrosis (P = 0.35), cirrhosis (P = 0.74), hepatitis B virus (P = 0.31), or hepatitis C virus (P = 0.15). Overall survival tended to be longer in patients without versus with PSMA expression (median overall survival: 4.2 vs. 1.9 years; P = 0.273). FGF14 (fibroblast growth factor 14) mRNA expression correlated positively (rho = 0.70; P = 1.70 × 10‐5) and MAD1L1 (Mitotic spindle assembly checkpoint protein MAD1) correlated negatively with PSMA expression (rho = −0.753; P = 1.58 × 10‐6). Of the 190 patients who met the eligibility criteria, 31 patients with 39 HCC lesions completed PET; 64% (n = 25) lesions had pronounced 68Ga‐PSMA‐11 standardized uptake value: SUVmax (median [range] 9.2 [4.9‐28.4]), SUVmean 4.7 (2.4‐12.7), and tumor‐to‐liver background ratio 2 (1.1‐11). Conclusion: Ex vivo expression of PSMA in neovasculature of HCC translates to marked tumor avidity on 68Ga‐PSMA‐11 PET, which suggests that PSMA has the potential as a theranostic target in patients with HCC.